Upstream’s library of novel compounds has demonstrated encouraging potential in vitro against the tropical parasitic diseases leishmaniasis and trypanosomiasis, and may also have therapeutic utility against the parasite that causes malaria.
Joel Bellenson, CEO of Upstream, said: “We look forward to moving quickly to complete these initial studies so that we can hopefully progress to further preclinical and clinical studies of the candidates that demonstrate the most promise for the treatment of malaria.”